Published on 19 Nov 2023 on Simply Wall St. via Yahoo Finance
CEO & Director of Heron Therapeutics Craig Collard Buys 411% More Shares
Investors who take an interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) should definitely note that the CEO & Director, Craig Collard, recently paid US$0.92 per share to buy US$138k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 411%, potentially signalling some real optimism.
Check out our latest analysis for Heron Therapeutics
Heron Therapeutics Insider Transactions Over The Last Year